Cue Biopharma, Inc. (CUE)

Price$29.46

Value ScoreC

Growth ScoreA

Momentum ScoreA

Favorite Metrics

Price vs S&P 500 (26W)47.95%

Price vs S&P 500 (4W)-15.82%

VGM Score77.08

Market Capitalization$119.19M

All Metrics

Book Value / Share (Quarterly)$6.64

P/TBV (Annual)3.15x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)180.09%

Cash Flow / Share (Quarterly)$-7.56

Price vs S&P 500 (YTD)213.81%

Net Profit Margin (TTM)-59.65%

EPS (TTM)$-5.52

10-Day Avg Trading Volume0.08M

EPS Excl Extra (TTM)$-5.52

Revenue Growth (5Y)54.20%

EPS (Annual)$-8.43

ROI (Annual)-100.64%

Net Profit Margin (5Y Avg)-1199.06%

Cash / Share (Quarterly)$5.03

Revenue Growth QoQ (YoY)1250.59%

ROA (Last FY)-63.02%

Revenue Growth TTM (YoY)309.60%

EBITD / Share (TTM)$-5.16

ROE (5Y Avg)-123.60%

Operating Margin (TTM)-59.90%

Cash Flow / Share (Annual)$-6.79

P/B Ratio5.52x

P/B Ratio (Quarterly)1.04x

Net Income / Employee (Annual)$-917,300

EV / Revenue (TTM)3.14x

ROA (TTM)-53.69%

EPS Incl Extra (Annual)$-8.43

Current Ratio (Annual)2.74x

Quick Ratio (Quarterly)3.34x

3-Month Avg Trading Volume0.53M

52-Week Price Return55.87%

Revenue / Employee (TTM)$1,128,700

Tangible BV / Share (Quarterly)$1.95

P/S Ratio (Annual)4.34x

Asset Turnover (Annual)0.65x

52-Week High$41.42

Operating Margin (5Y Avg)-1208.72%

EPS Excl Extra (Annual)$-8.43

CapEx CAGR (5Y)-21.66%

Tangible BV CAGR (5Y)1.35%

26-Week Price Return55.87%

Quick Ratio (Annual)2.64x

13-Week Price Return240.97%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.57x

Enterprise Value$102.81M

Revenue / Share Growth (5Y)139.76%

Asset Turnover (TTM)0.90x

Book Value / Share Growth (5Y)25.85%

Revenue / Employee (Annual)$947,100

Pretax Margin (Annual)-95.03%

Cash / Share (Annual)$8.43

3-Month Return Std Dev333.62%

Net Income / Employee (TTM)$-673,200

ROE (Last FY)-100.64%

EPS Basic Excl Extra (Annual)$-8.43

Receivables Turnover (TTM)12.23x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-5.52

Receivables Turnover (Annual)8.46x

ROI (TTM)-93.30%

P/S Ratio (TTM)3.64x

Pretax Margin (5Y Avg)-1198.04%

Revenue / Share (Annual)$8.70

Tangible BV / Share (Annual)$3.69

Price vs S&P 500 (52W)31.51%

Year-to-Date Return221.97%

5-Day Price Return22.42%

EPS Normalized (Annual)$-8.43

ROA (5Y Avg)-76.57%

Net Profit Margin (Annual)-96.85%

Month-to-Date Return34.52%

Cash Flow / Share (TTM)$-1.17

EBITD / Share (Annual)$-8.30

Operating Margin (Annual)-96.67%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-107.31%

LT Debt / Equity (Quarterly)0.01x

EPS Basic Excl Extra (TTM)$-5.52

P/TBV (Quarterly)4.48x

P/B Ratio (Annual)1.05x

Pretax Margin (TTM)-58.12%

Book Value / Share (Annual)$8.21

Price vs S&P 500 (13W)232.72%

Beta2.48x

Revenue / Share (TTM)$6.81

ROE (TTM)-98.30%

52-Week Low$4.97

vGradeC

gGradeA

mGradeA

vgmGradeB

Show chart for

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.00

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
CUECue Biopharma, Inc.	C	A	A	$29.46
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Cue Biopharma is a clinical-stage biopharmaceutical company developing a proprietary class of biologics designed to selectively modulate the immune system for treating cancer and autoimmune diseases. The company's pipeline includes CUE-101 (alone and in combination with Pembrolizumab), CUE-102, CUE-103, and other candidates leveraging its immune modulation platform.